Navigation Links
Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients
Date:5/20/2008

- Study shows significantly improved bronchodilation and symptom control

with combination therapy -

NAPA, Calif., May 20 /PRNewswire/ -- A newly published study presents data demonstrating that patients with Chronic Obstructive Pulmonary Disease (COPD), including emphysema and chronic bronchitis, experienced markedly improved bronchodilation and symptom control when treated with a combination of nebulized formoterol fumarate inhalation solution (Perforomist(TM) Inhalation Solution) and tiotropium (TIO), compared to treatment with tiotropium alone. The two medications, when used adjunctively, were also well tolerated by patients over the course of the 6-week study.

"Concomitant Treatment with Nebulized Formoterol and Tiotropium in Subjects with COPD: A Placebo-Controlled Trial," published in Respiratory Medicine, assesses the efficacy and safety of the concomitant treatment of Perforomist(TM) nebulized formoterol fumarate (a long-acting beta-agonist [LABA]) and tiotropium (an anticholinergic) in 130 adults with moderate to severe COPD.

"These data provide additional insight into the additive benefit of concomitant therapy with a LABA and a long-acting anticholinergic," said Dr. Donald Tashkin, MD, FACP, FCCP, Professor of Medicine, David Geffen School of Medicine at the University of California at Los Angeles, lead author and principal investigator of the study. "When Perforomist(TM) Solution's rapid onset of action is combined with tiotropium's prolonged bronchodilation, the result appears to be a safe and effective treatment option for patients. This is great news for the millions of patients -- and their families -- who live with COPD, and who too often struggle with an insufficient number of robust treatment options."

About the Study

The study was a six-week, randomized, double-blind, placebo-controlled, parallel-group design study. COPD patients entered a 7-14 day run-in period during which subje
'/>"/>

SOURCE Dey, L.P.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone
2. Clinical Trial Data on the Safety and Efficacy of Concomitant Formoterol Fumarate/ Tiotropium Treatment for COPD
3. New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease
4. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
5. Early Esophageal Cancer and Pre-Cancer Eliminated With Non-Surgical Treatment Combination
6. Data Show Rufinamide, an Investigational Adjunctive Treatment for Lennox- Gastaut Syndrome, Reduced Drop Attacks by More Than 40%
7. Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib)
8. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
9. RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
10. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
11. Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... BETHESDA, Md. , June 19, 2013 /PRNewswire/ -- ... "Company"), an American healthcare company providing services in ... of United Family Healthcare, a network of private ... official opening of its Beijing United Family Rehabilitation ... development projects of the United Family Healthcare ("UFH") ...
(Date:6/19/2013)... N.Y. , June 19, 2013 ... sourcing company servicing all branches of government from ... they have expanded their facilities to include complex ... designed and fabricated some very complex aluminum parts ... continue to expand our capabilities to service government ...
(Date:6/19/2013)... June 19, 2013 DST Health Solutions, LLC ... to health plans, integrated delivery systems, and health care ... Drug Management Service (MDMS) has jumped significantly. ... automate the pricing of medical prescription drug claims, MDMS ... automating their medical drug claims processes. As specialty drug ...
Breaking Medicine Technology:Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 2Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 3Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 4Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 5Amerivet Solutions Expands to Manufacture Complex Metal Designs 2Demand For DST's Medical Drug Management Service On The Rise As Health Plan Costs Increase 2Demand For DST's Medical Drug Management Service On The Rise As Health Plan Costs Increase 3
... 27 ChemoCentryx, Inc., today announced that ... PROTECT-1 Study (the Prospective Randomized Oral Therapy ... (CCX282-B) in patients with moderate-to-severe Crohn,s disease. ... antagonist showed clinical efficacy in a 12-week ...
... NANJING, China, Oct. 27 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ... specializing in the development, manufacturing, and marketing of branded ... it will report its unaudited financial results for the ... 11, 2010, before the market opens in the United ...
Cached Medicine Technology:ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Treating Patients with Crohn's Disease at the United European Gastroenterology Federation (UEGW) Meeting 2ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Treating Patients with Crohn's Disease at the United European Gastroenterology Federation (UEGW) Meeting 3ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Treating Patients with Crohn's Disease at the United European Gastroenterology Federation (UEGW) Meeting 4ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Treating Patients with Crohn's Disease at the United European Gastroenterology Federation (UEGW) Meeting 5Simcere Pharmaceutical Group to Announce Third Quarter 2010 Financial Results on Thursday, November 11, 2010 2
(Date:6/19/2013)... Arbor, Mich. Children had half as many ... evening office hours on five or more days a ... at C.S. Mott Children,s Hospital and Johns Hopkins University. ... in The Journal of Pediatrics and will ... "These findings are an important step in understanding where ...
(Date:6/19/2013)... ROCHESTER, Minn. -- Nearly 70 percent of ... and more than half take two, Mayo Clinic ... most commonly prescribed, their study found. Twenty percent ... medications, according to the findings, published online in ... MULTIMEDIA ALERT: For audio and video of Dr. ...
(Date:6/19/2013)... June 19, 2013 North Carolina-based ... organizational changes to advance development of its technologies. ... “To support the advanced development of our product ... to the Company’s management structure and engaged industry ... Company announced that Michael Galiger will serve as ...
(Date:6/19/2013)... Brightree LLC , the leading provider of ... post-acute care industry, has been ranked for the first time ... 100 (HCI 100) list. This prestigious list features the ... of revenue during the last fiscal year. Since 2005, Brightree’s ... and the company has built its organization to more than ...
(Date:6/19/2013)... Many trying-to-conceive couples seek medical ... according to a recent study published ... results of this research confirm what Fairhaven Health ... – that trying-to-conceive women would benefit from tracking ... weight. Fairhaven Health is a leading provider of ...
Breaking Medicine News(10 mins):Health News:Extended primary care office hours might help keep kids out of the emergency department 2Health News:Nearly 7 in 10 Americans are on prescription drugs, Mayo Clinic study finds 2Health News:Entegrion Announces Organizational Changes to Support Advanced Product Development 2Health News:Entegrion Announces Organizational Changes to Support Advanced Product Development 3Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 2Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 3Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 2Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 3Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 4
... More than 90% of drugs entering,clinical development fail ... of,effectiveness or adverse side effects not detected in ... pre-clinical tests using stem cell,technologies, potentially saving drug ... Cells: Worldwide Markets for,Transplantation, Cord Blood Banking and ...
... condition associated with pregnancy responds to energy restoration, ... the editor,in today,s USA Today, board-certified cardiologist Stephen T. ... a rare and often,misunderstood form of heart disease. Responding ... twins who developed peripartum cardiomyopathy, an,uncommon and mystifying type ...
... Transcept,Pharmaceuticals, Inc. today announced that Glenn A. ... the BioCentury "Future,Leaders in the Biotech Industry" Conference ... New York City on Thursday, March 27, 2008 ... Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical ...
... GlaxoSmithKline (NYSE: GSK ),today reported its ... equivalent to almost 4% of pre-tax profits for ... Donations of albendazole treatments,for the company,s flagship program ... valued at $29 million, bringing the,total number of ...
... of natural compound found in heparin samples , , WEDNESDAY, ... they,ve identified the contaminant found in the blood-thinner heparin, ... and possibly 19 deaths in the United States. , ... sulfate, but U.S. Food and Drug Administration officials could ...
... Profits before ... Patients, ST. ... their side, International Union of Operating,Engineers Local 49 leaders today at a ... off medical coverage to,several thousand Minnesota seniors., "This is a death ...
Cached Medicine News:Health News:Stem Cell Technology Offers Promise of Huge Savings for Drug Developers 2Health News:Metabolic Cardiologist Offers New Hope for Women With Heart Disease 2Health News:GSK Charitable Support Valued at $564 Million in 2007 2Health News:GSK Charitable Support Valued at $564 Million in 2007 3Health News:FDA Identifies Contaminant in Blood-Thinning Drug 2Health News:FDA Identifies Contaminant in Blood-Thinning Drug 3Health News:Park Nicollet to Cut Off Care to Thousands of Minnesota Seniors 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: